Global AI Cardiovascular Screening System Supply, Demand and Key Producers, 2026-2032
Description
The global AI Cardiovascular Screening System market size is expected to reach $ 2651 million by 2032, rising at a market growth of 23.9% CAGR during the forecast period (2026-2032).
AI Cardiovascular Screening Systems are artificial intelligence–enabled solutions designed to support the early identification and risk stratification of cardiovascular diseases through non-invasive imaging and physiological data analysis. Unlike diagnostic systems used for definitive clinical confirmation, these systems focus on screening and triage, aiming to detect potential abnormalities at an early stage and prioritize patients for further evaluation. Typical inputs include echocardiography, vascular ultrasound, ECG, blood pressure data, and increasingly multimodal datasets. AI models automate tasks such as view recognition, automated measurements (e.g., chamber size, ejection fraction surrogates), abnormal pattern detection, and population-level risk scoring. These systems are widely applied in outpatient clinics, health check-up centers, primary care, and community screening programs, where efficiency, consistency, and scalability are critical.
From a multi-dimensional classification perspective, the market can be parameterized by screening modality (cardiac ultrasound–based, vascular ultrasound–based, ECG-based, or multimodal screening), target population (general population screening, high-risk groups such as hypertension or diabetes patients, occupational or elderly screening), AI functional scope (automated measurements, abnormality flagging, risk stratification, workflow triage), and deployment model (on-device embedded systems, hybrid edge–cloud platforms, or centralized cloud screening services). Regulatory positioning also differentiates solutions into research or wellness-oriented screening tools versus clinically validated screening systems cleared for medical use.
The value chain starts upstream with imaging device manufacturers, sensor and semiconductor suppliers, and data infrastructure providers. Midstream players include AI algorithm developers, cardiovascular software vendors, and system integrators responsible for embedding screening AI into existing ultrasound, ECG, or health IT platforms. Downstream customers consist of hospitals, outpatient cardiology clinics, primary care networks, health screening centers, and public health organizations. Partnerships with device OEMs and healthcare providers are particularly important, as screening systems must integrate smoothly into high-throughput workflows and existing information systems.
From an economic perspective, AI cardiovascular screening systems benefit from a software-heavy cost structure, with R&D, data annotation, clinical validation, and regulatory compliance representing the largest fixed costs. Once deployed at scale, incremental screening costs are relatively low, supporting favorable gross margins compared with traditional hardware-centric solutions. Market trends point toward rapid growth driven by aging populations, rising cardiovascular disease prevalence, expansion of preventive healthcare, and increasing adoption of AI-enabled point-of-care screening. Future developments are expected to include broader multimodal screening platforms, deeper integration with population health management systems, and wider use in large-scale preventive and community-based screening programs.
This report studies the global AI Cardiovascular Screening System demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for AI Cardiovascular Screening System, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of AI Cardiovascular Screening System that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global AI Cardiovascular Screening System total market, 2021-2032, (USD Million)
Global AI Cardiovascular Screening System total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: AI Cardiovascular Screening System total market, key domestic companies, and share, (USD Million)
Global AI Cardiovascular Screening System revenue by player, revenue and market share 2021-2026, (USD Million)
Global AI Cardiovascular Screening System total market by Type, CAGR, 2021-2032, (USD Million)
Global AI Cardiovascular Screening System total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global AI Cardiovascular Screening System market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GE Healthcare, Philips, UltraSight, Us2.ai, Ultromics, Butterfly Network, Exo Imaging, Canon Medical, Mindray, Samsung Medison, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world AI Cardiovascular Screening System market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global AI Cardiovascular Screening System Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global AI Cardiovascular Screening System Market, Segmentation by Type:
Ultrasound-based Screening
ECG-based Screening
Multimodal Imaging Screening
Non-imaging Signal-based Screening
Hybrid Clinical Data Screening
Global AI Cardiovascular Screening System Market, Segmentation by Deployment & Integration Model:
On-device / Embedded AI Solutions
Hybrid Edge–Cloud AI Platforms
AI Plug-ins for Existing Ultrasound Systems
Others
Global AI Cardiovascular Screening System Market, Segmentation by AI Functional Depth:
Scan Guidance & View Recognition
Automated Measurement & Quantification
Structural & Functional Abnormality Detection
Disease Classification & Risk Stratification
Others
Global AI Cardiovascular Screening System Market, Segmentation by Application:
Medical Institutions
Great Health Scene
Companies Profiled:
GE Healthcare
Philips
UltraSight
Us2.ai
Ultromics
Butterfly Network
Exo Imaging
Canon Medical
Mindray
Samsung Medison
Clarius Mobile Health
HEBIN
Demetics Medical Technology
Shukun Technology
Shenzhen Keya Medical Technology（）
Key Questions Answered
1. How big is the global AI Cardiovascular Screening System market?
2. What is the demand of the global AI Cardiovascular Screening System market?
3. What is the year over year growth of the global AI Cardiovascular Screening System market?
4. What is the total value of the global AI Cardiovascular Screening System market?
5. Who are the Major Players in the global AI Cardiovascular Screening System market?
6. What are the growth factors driving the market demand?
AI Cardiovascular Screening Systems are artificial intelligence–enabled solutions designed to support the early identification and risk stratification of cardiovascular diseases through non-invasive imaging and physiological data analysis. Unlike diagnostic systems used for definitive clinical confirmation, these systems focus on screening and triage, aiming to detect potential abnormalities at an early stage and prioritize patients for further evaluation. Typical inputs include echocardiography, vascular ultrasound, ECG, blood pressure data, and increasingly multimodal datasets. AI models automate tasks such as view recognition, automated measurements (e.g., chamber size, ejection fraction surrogates), abnormal pattern detection, and population-level risk scoring. These systems are widely applied in outpatient clinics, health check-up centers, primary care, and community screening programs, where efficiency, consistency, and scalability are critical.
From a multi-dimensional classification perspective, the market can be parameterized by screening modality (cardiac ultrasound–based, vascular ultrasound–based, ECG-based, or multimodal screening), target population (general population screening, high-risk groups such as hypertension or diabetes patients, occupational or elderly screening), AI functional scope (automated measurements, abnormality flagging, risk stratification, workflow triage), and deployment model (on-device embedded systems, hybrid edge–cloud platforms, or centralized cloud screening services). Regulatory positioning also differentiates solutions into research or wellness-oriented screening tools versus clinically validated screening systems cleared for medical use.
The value chain starts upstream with imaging device manufacturers, sensor and semiconductor suppliers, and data infrastructure providers. Midstream players include AI algorithm developers, cardiovascular software vendors, and system integrators responsible for embedding screening AI into existing ultrasound, ECG, or health IT platforms. Downstream customers consist of hospitals, outpatient cardiology clinics, primary care networks, health screening centers, and public health organizations. Partnerships with device OEMs and healthcare providers are particularly important, as screening systems must integrate smoothly into high-throughput workflows and existing information systems.
From an economic perspective, AI cardiovascular screening systems benefit from a software-heavy cost structure, with R&D, data annotation, clinical validation, and regulatory compliance representing the largest fixed costs. Once deployed at scale, incremental screening costs are relatively low, supporting favorable gross margins compared with traditional hardware-centric solutions. Market trends point toward rapid growth driven by aging populations, rising cardiovascular disease prevalence, expansion of preventive healthcare, and increasing adoption of AI-enabled point-of-care screening. Future developments are expected to include broader multimodal screening platforms, deeper integration with population health management systems, and wider use in large-scale preventive and community-based screening programs.
This report studies the global AI Cardiovascular Screening System demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for AI Cardiovascular Screening System, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of AI Cardiovascular Screening System that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global AI Cardiovascular Screening System total market, 2021-2032, (USD Million)
Global AI Cardiovascular Screening System total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: AI Cardiovascular Screening System total market, key domestic companies, and share, (USD Million)
Global AI Cardiovascular Screening System revenue by player, revenue and market share 2021-2026, (USD Million)
Global AI Cardiovascular Screening System total market by Type, CAGR, 2021-2032, (USD Million)
Global AI Cardiovascular Screening System total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global AI Cardiovascular Screening System market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GE Healthcare, Philips, UltraSight, Us2.ai, Ultromics, Butterfly Network, Exo Imaging, Canon Medical, Mindray, Samsung Medison, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world AI Cardiovascular Screening System market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global AI Cardiovascular Screening System Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global AI Cardiovascular Screening System Market, Segmentation by Type:
Ultrasound-based Screening
ECG-based Screening
Multimodal Imaging Screening
Non-imaging Signal-based Screening
Hybrid Clinical Data Screening
Global AI Cardiovascular Screening System Market, Segmentation by Deployment & Integration Model:
On-device / Embedded AI Solutions
Hybrid Edge–Cloud AI Platforms
AI Plug-ins for Existing Ultrasound Systems
Others
Global AI Cardiovascular Screening System Market, Segmentation by AI Functional Depth:
Scan Guidance & View Recognition
Automated Measurement & Quantification
Structural & Functional Abnormality Detection
Disease Classification & Risk Stratification
Others
Global AI Cardiovascular Screening System Market, Segmentation by Application:
Medical Institutions
Great Health Scene
Companies Profiled:
GE Healthcare
Philips
UltraSight
Us2.ai
Ultromics
Butterfly Network
Exo Imaging
Canon Medical
Mindray
Samsung Medison
Clarius Mobile Health
HEBIN
Demetics Medical Technology
Shukun Technology
Shenzhen Keya Medical Technology（）
Key Questions Answered
1. How big is the global AI Cardiovascular Screening System market?
2. What is the demand of the global AI Cardiovascular Screening System market?
3. What is the year over year growth of the global AI Cardiovascular Screening System market?
4. What is the total value of the global AI Cardiovascular Screening System market?
5. Who are the Major Players in the global AI Cardiovascular Screening System market?
6. What are the growth factors driving the market demand?
Table of Contents
121 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World AI Cardiovascular Screening System Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Deployment & Integration Model
- 7 Market Analysis by AI Functional Depth
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
